Trial Profile
A Phase 1 Study of Trametinib in Combination With Chemoradiation for KRAS Mutant Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Trametinib (Primary) ; Carboplatin; Paclitaxel; Ropidoxuridine
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- 04 May 2023 Status changed from active, no longer recruiting to discontinued.
- 07 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2018.